Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US.

ABSTRACT:

Importance

The treatment landscape of metastatic clear cell renal cell carcinoma (ccRCC) has rapidly evolved with the approval of multiple immune checkpoint inhibitor (ICI)-based combinations. However, clinical data on changes in treatment patterns and attrition before and after ICI-based combinations approval are lacking.

Objective

To assess treatment patterns and attrition rates in patients with metastatic ccRCC before and after the approval of ICI-based combinations.

Design, setting, and participants

This cohort study used patient-level data from a nationwide deidentified electronic health record-derived database, originating from around 280 cancer clinics in the US. Patients diagnosed with metastatic ccRCC who received first-line therapy between January 1, 2011, a

SUBMITTER: Ozay ZI 

PROVIDER: S-EPMC11926653 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature